The IkB kinase (IKKa, b and the regulatory subunit IKKg) complex regulates nuclear factor of kB (NF-kB) transcriptional activity, which is upregulated in many chronic inflammatory diseases. NF-kB signaling promotes inflammation and limits muscle regeneration in Duchenne muscular dystrophy (DMD), resulting in fibrotic and fatty tissue replacement of muscle that exacerbates the wasting process in dystrophic muscles. Here, we examined whether dominant-negative forms of IKKa (IKKa-dn) and IKKb (IKKb-dn) delivered by adeno-associated viral (AAV) vectors to the gastrocnemius (GAS) and tibialis anterior (TA) muscles of 1, 2 and 11-month-old mdx mice, a murine DMD model, block NF-kB activation and increase muscle regeneration. At 1 month post-treatment, the levels of nuclear NF-kB in locally treated muscle were decreased by gene transfer with either AAV-CMV-IKKa-dn or AAV-CMV-IKKb-dn, but not by IKK wild-type controls (IKKa and b) or phosphate-buffered saline (PBS). Although treatment with AAV-IKKa-dn or AAV-IKKbdn vectors had no significant effect on muscle regeneration in young mdx mice treated at 1 and 2 months of age and collected 1 month later, treatment of old (11 months) mdx with AAV-CMV-IKKa-dn or AAV-CMV-IKKb-dn significantly increased levels of muscle regeneration. In addition, there was a significant decrease in myofiber necrosis in the AAVIKKa-dn-and AAV-IKKb-dn-treated mdx muscle in both young and old mice. These results demonstrate that inhibition of IKKa or IKKb in dystrophic muscle reduces the adverse effects of NF-kB signaling, resulting in a therapeutic effect. Moreover, these results clearly demonstrate the therapeutic benefits of inhibiting NF-kB activation by AAV gene transfer in dystrophic muscle to promote regeneration, particularly in older mdx mice, and block necrosis.
Introduction
Duchenne muscular dystrophy (DMD) is the most common muscular dystrophy and is caused by recessive mutations in the dystrophin gene. 1 Progressive muscle weakness and degeneration usually lead to loss of independent ambulation by the middle of the second decade and a fatal outcome because of cardiac or respiratory failure by the third decade. 2 In DMD patients, loss of sarcolemmal dystrophin and the dystrophinassociated glycoprotein complex promotes muscle fiber damage during muscle contraction. [3] [4] [5] [6] [7] This process results in efflux of creatine kinase, influx of calcium ions and recruitment of T cells, macrophages and mast cells to the damaged muscle, causing progressive myofiber necrosis. 2 Muscle regeneration is the initial response to damage, but muscle progenitor cells are exhausted with continued cycles of necrosis over time, thus giving way to accumulated fibrosis and fatty deposits that exacerbate the wasting process in DMD. 8 Currently, there are no effective treatments available for DMD. Adeno-associated viral (AAV) vector-mediated gene transfer of minidystrophin has shown great promise in mouse models, but did not completely prevent fibrosis and necrosis in dystrophic muscles or reverse the muscle wasting process in the dystrophin/utrophin double-knockout mouse, a DMD model with genetic loss of both dystrophin and utrophin. [9] [10] [11] The efficacy of AAVmediated mini-dystrophin gene transfer to ameliorate the muscle wasting process is limited, in part, by the inflammatory microenvironment. Therefore, the ability to modulate chronic inflammation in dystrophic muscle is important for optimizing therapeutic strategies to treat muscle wasting and DMD.
Nuclear factor kB (NF-kB) is a ubiquitously expressed transcription factor in mammals. In the classical activation pathway, NF-kB signaling occurs primarily by way of a p50/p65 heterodimer. 12 In most cells, the majority of NF-kB is localized in the cytoplasmic compartment, maintained in an inactive state by binding to the inhibitor of NF-kB (IkB). 13 The classical pathway of NF-kB activation occurs through IkB kinase (IKK), a large 700-900 kDa complex containing two catalytic subunits, IKKa and IKKb, and a regulatory subunit IKKg.
14 In response to a multitude of factors, including lipopolysaccharide (LPS), tumor necrosis factor a (TNFa), interleukin-1b (IL-1b) and IL-6, IKK is activated and phosphorylates IkB, leading to its ubiquitination and subsequent degradation by the 26S proteasome. 15 IkB degradation allows the translocation of the NF-kB heterodimer to the nucleus where it binds to its cognate DNA site and interacts with the basal transcription factors and coactivators to induce gene expression. 16 NF-kB has a key role promoting the inflammatory response in muscular dystrophy. 17, 18 Elevated levels of NF-kB have been detected in more than one type of muscular dystrophy, including DMD 19 and limb-girdle muscular dystrophy. 20 A recent study demonstrated that chronic activation of NF-kB signaling, often mediated by IKKb, is required for DMD pathology by acting both on immune cells and damaged skeletal muscles to promote inflammation and inhibit myogenic differentiation of muscle precursors in mdx mice. 19 Although IKKa regulates the muscle mitochondrial content and function, 21 it is unclear whether IKKa is involved in chronic inflammation in dystrophic muscle. The p65 subunit of NF-kB was implicated in regulating muscle pathology in mdx mice by a genetic experiment in which dystrophindeficient mdx mice were bred with mice that carry a heterozygous deletion of the p65. The mdx-heterozygous p65 cross resulted in improved dystrophic pathology characterized by enhanced muscle regeneration. 22 Also, targeted ablation of IKKb was found to improve the morphological and functional phenotypes of mdx muscle. 22 Collectively, these studies demonstrate the critical role of IKK/NF-kB signaling in the progression of DMD and implicate the NF-kB signaling pathway as a potential therapeutic target for this disease.
More recently, modulation of NF-kB by systemic treatment with a synthetic antioxidant such as pyrrolidine dithiocarbamate 17 or with a peptide inhibitor of IKKb, 22 reduced inflammation and necrosis while enhancing regeneration. However, these approaches require repeated treatments and have the potential for systemic side effects. AAV-based gene therapy is a promising therapeutic approach for the treatment of DMD, as demonstrated by pre-clinical studies in mdx or double-knockout mouse 9, 23, 24 and canine models. 25 We, therefore, tested the therapeutic effects of treatment with AAV vectors carrying either a dominant-negative IKKa (IKKa-dn) or IKKb (IKKb-dn). The efficacy of AAV vector-mediated IKKa-dn and IKKb-dn gene transfer was assessed in locally treated skeletal muscle of young and old mdx mice.
Results

Dominant-negative IKK (IKKb-dn) blocks the NF-kB pathway in mouse macrophages
We generated AAV-based vectors carrying the cDNAs for dominant-negative mutants (IKKa-dn and IKKb-dn) and wild-type IKKa and IKKb (IKKa-wt and IKKb-wt). To confirm that the vectors expressed functional proteins, the ability of AAV-IKKb-dn and AAV-IKKb-wt to regulate activation of NF-kB was examined by measuring TNFa and IL-10 expression following transduction of mouse macrophages, called RAW cells. Following treatment of the macrophages with LPS stimulation, there was a reduction in the levels of TNFa and IL-10 in the culture medium of the IKKb-dn-treated cells compared with either IKKb-wt+LPS (*Po0.05) or LPS groups ( # Po0.05). Moreover, we found that the IKKb-wt treatment resulted in increased TNFa level compared with the LPS control group ( & Po0.05). In contrast, there was no significant difference of IL-10 between IKKb-wt+LPS and the LPS group (Table 1) . These results demonstrated that AAV-IKKb-dn blocks the NF-kB signaling pathway in mouse macrophages, resulting in decreased levels of pro-inflammatory cytokines such as TNFa and IL-10. We observed that AAV-IKKb-dn decreased TNFa by a twoto threefold margin, whereas IL-10 was decreased as much as 10-to 15-fold.
Efficiency of gene transfer in vitro
Before the in vivo gene transfer experiment, we observed successful AAV-mediated gene transfer with dominantnegative forms of IKKs (IKKa-dn and IKKb-dn) and IKK wild-type controls (IKKa and b) into 293 cells, a human embryonic kidney cell line. As the given mutations in dominant-negative forms of IKKa-dn and IKKb-dn were closed to N-terminus, the antibody against C-terminus of IKKa or IKKb was used to test gene expression of IKKa-(dn and wt) or IKKb-(dn and wt). As depicted in Figure 1a , in initial study, western blot analysis showed highly efficient transductions were found in infected cells 48 h post-infection, respectively, by AAV2-IKKa-dn, AAV2-IKKa-wt, AAV2-IKKb-dn and AAV2-IKKb-wt, no gene expression was in phosphate-buffered saline (PBS) control group. No significant difference was found between IKKb-dn and IKKb-wt in infected cells; however, the level of IKKa-wt was higher than IKKa-dn in infected cells because of the antibody against C-terminus of wild-type IKKa.
AAV gene transfer of IKKa-dn and IKKb-dn reduces nuclear NF-kB in mdx muscle
To evaluate the AAV-mediated effects of both IKKa-dn and IKKb-dn on the treatment of dystrophic muscle wasting, we locally treated skeletal muscle of both young Inhibition of the NF-jB pathway by gene transfer improves dystrophic muscles in Mdx mice Y Tang et al and old mdx mice, and analyzed the levels of nuclear NF-kB at 1 month after a single intramuscular AAV injection. The efficiencies of AAV-mediated gene transfer in muscles were determined by a western blot analysis 1 month post-treatment. As shown in Figure 1b , there were marked increases in IKKa-(dn and wt) and IKKb-(dn and wt) activities in gastrocnemius (GAS) treated at 2 months of age and tibialis anterior (TA) muscles treated at 11 months of age when compared with PBS-treated controls. To determine whether the IKKa-dn and IKKb-dn could inhibit IKK/NF-kB pathway by decreasing the level of nuclear NF-kB, we also tested the level of nuclear NF-kB 1 month after treatment. As expected, the levels of nuclear NF-kB in GAS and TA muscles treated by AAVIKKa-dn and IKKb-dn at different age groups (1, 2 and 11 months) were much lower compared with AAV-IKKawt, AAV-IKKb-wt and PBS controls in age-matched mdx mice ( Figure 1c ). This indicates that not only IKKb-dn, but also IKKa-dn decreased the levels of nuclear NF-kB in locally treated dystrophic muscle. In contrast, the levels of nuclear NF-kB in young and old mdx mice treated with a vector carrying either wild-type IKKa or wild-type IKKb were similar to the PBS control group.
No effect on muscle regeneration of AAV-IKKa-dn-and AAV-IKKb-dn-treated young mdx muscle
We investigated the therapeutic effects of the AAVmediated gene transfer of IKKa-dn and IKKb-dn on muscle regeneration in 1-and 2-month-old mdx mice (young mice). At 1 month post-treatment, the dystrophic muscle regeneration, as measured by the number of embryonic myosin heavy chain positive myofibers, was greater in mdx mice treated at 1 month of age compared with mdx mice treated at 2 months of age; however, there was no difference observed between treated and untreated mdx at the same age ( Figure 2a ; Table 2 ). These results suggest that abnormal muscle regeneration is higher in dystrophic mice at 2 months of age compared with 3 months of age, likely by the induction of satellite cells into myofibers, which is consistent with previous studies.
26
Improved muscle regeneration in AAV-IKKa-dn-and AAV-IKKb-dn-treated old mdx muscle
To investigate whether muscle regeneration could be improved in old mdx mice even when the regenerative capacity of progenitor or myogenic cells becomes exhausted, 27 we examined the therapeutic effects of AAV-IKKa-dn or AAV-IKKb-dn gene transfer in 11-month-old mdx mice. Interestingly, there was increased muscle regeneration in both GAS and TA muscles of older mdx mice treated by IKKa-dn and IKKb-dn, in contrast to AAV-IKKa-wt, AAV-IKKb-wt and PBS-treated controls ( Figure 2b ; Table 2 ). These results demonstrate a therapeutic effect of NF-kB inhibition evidenced by enhances regeneration of dystrophic skeletal muscle tissue in old mdx mice.
Decreased muscle fiber necrosis in IKKa-dn-and IKKb-dn-treated young and old mdx muscle Chronic inflammation is a feature of the dystrophic muscle pathology in DMD and likely exacerbates the dystrophic muscle wasting process. To determine whether AAV-IKKa-dn-or AAV-IKKb-dn-treated muscle demonstrates a decrease in the level of muscle fiber necrosis, sections were incubated with fluorescently labeled mouse IgG. At 1 month post-treatment, a significant decrease in myofiber necrosis was found in One month after intramuscular gene transfer with four different AAV2 vectors, the cryosections of GAS muscles treated at 2 months of age and TA muscles treated at 11 months of age were determined the efficiencies of gene transfer by western blot analysis. The increased levels of IKKa-(dn and wt) and IKKb-(dn and wt) were found in AAV2-IKKa-dn-, AAV2-IKKa-wt-, AAV2-IKKb-dn-and AAV2-IKKb-wt-treated young and old mdx muscles compared with PBS-treated mdx muscle at same age. (c) The electrophoretic mobility shift assay demonstrates the level of nuclear NF-kB in the gastrocnemius (GAS) muscle of both 1-and 2-month-old young mdx mice and the tibialis anterior (TA) muscle of 11-month-old mdx mice treated by AAV2-IKKa-dn, AAV2-IKKa-wt, AAV2-IKKb-dn, AAV2-IKKb-wt and PBS. A total of 45 mg of nuclear extract from each mouse was analyzed at 1 month post-treatment.
Inhibition Inhibition of the NF-jB pathway by gene transfer improves dystrophic muscles in Mdx mice Y Tang et al muscles treated with either AAV-IKKa-dn or AAV-IKKbdn at the age of 1, 2 and 11 months. In contrast, muscle treated with AAV-IKKa-wt, AAV-IKKb-wt or PBS showed extensive myofiber necrosis ( Figure 3 ; Table 2 ).
Discussion
Progressive muscle degeneration and wasting leads to pre-mature death in DMD patients. 1, 2 The accumulation of fibrotic and necrotic tissue in dystrophic muscle exacerbates the wasting process. Fibrosis is the final result of chronic inflammation mediated, in part, by the pathological activation of NF-kB, in both muscle-infiltrating immune cells and damaged skeletal muscle fibers. 19 In our previous studies, AAV-mediated delivery of a mini-dystrophin gene resulted in efficient and functional recovery of dystrophic skeletal muscle in mdx mice; however, this approach was not sufficient to reverse the muscle wasting process or restore a normal life span in a severe murine model, the double-knockout mouse. [9] [10] [11] Despite noted successes in pre-clinical mouse studies, AAV mini-dystrophin gene transfer has limitations of partial transduction of muscle fibers and incomplete reversal of the dystrophic phenotype in muscle tissue. Thus, the development of methods to improve regeneration and block chronic inflammation in dystrophic muscle would not only offer direct therapeutic potential for DMD, but could also enhance the efficacy of gene therapy approaches.
In previous studies, blockade of the NF-kB signaling pathway with pharmacological agents has demonstrated success in delaying progression of the pathological features of dystrophy in mdx mice. 17, 28 Small molecules, including the use of an IKK inhibitory peptide, used to block pathological activation of NF-kB have improved muscle regeneration. However, the use of small molecules requires chronic, systemic treatment and raises concerns for potential systemic side effects. In contrast, a local gene transfer approach with gene transduction and transgene expression limited to muscle could impart a greater therapeutic effect with minimal adverse side effects. Therefore, inhibition of IKK/NF-kB signaling by a gene transfer-mediated approach could result in reducing progressive muscle loss and weakness. Tas et al. 29 used AAV to successfully deliver IKKb-dn (K4M) to the synovium, resulting in reduced severity of inflammation in adjuvant-induced arthritis in vivo and proinflammatory cytokine production in human rheumatoid arthritis synovial tissues ex vivo. Thus, in this study, we tested AAV-mediated gene transfer of IKKb-dn on muscle regeneration and necrosis in both young and old mdx mice. Moreover, as the role of IKKa in regulating muscle degeneration and regeneration as Figure 3 AAV-IKKs-dn inhibits muscle necrosis. Cryosections of muscle, from mice treated at 1, 2 and 11 months of age and killed 1 month after gene transfer, were incubated with fluorescently labeled mouse IgG. From left to right, many IgG positive necrotic (green) were found in GAS muscles treated by PBS (first panel), AAV2-IKKa-wt (third panel) and AAV2-IKKb-wt (fifth panel) in both 1-, 2-and 11-month-old groups. In contrast, the GAS muscle treated by AAV2-IKKa-dn (second panel) and AAV2-IKKb-dn (fourth panel) showed only few necrotic myofibers. All panels are shown at Â 100 magnification.
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The mdx mouse has a nonsense mutation in exon 23 of the dystrophin gene, resulting in pre-mature chain termination of the dystrophin protein. 30 Progressive pathological muscle necrosis and regeneration, 31, 32 are most marked between 1 and 2 months of age. 33 The satellite cell pool is diminished with advancing age of mdx mice because of the ongoing cycles of muscle degeneration and regeneration. 26 Hence, the AAV-mediated IKKa-dn and IKKb-dn treatment was first performed in young mdx mice. As summarized in Table 2 , we demonstrated that the level of myofiber necrosis (mice treated beginning at 1 and 2 months of age) was decreased in the AAV-IKKa-dn (19.7 and 15.0%) and AAV-IKKb-dn (17.8 and 13.1%) treated muscle of young mdx mice as compared with agematched control groups treated with PBS (26.9 and 24.5%), AAV-IKKa-wt (25.3 and 26.3%) and AAV-IKKb-wt (23.9 and 23.3%). This result suggests that the local treatment of the AAV-IKKa-dn and AAV-IKKb-dn can reduce the course of muscle necrosis.
In contrast to the effect on muscle fiber necrosis, there was no significant increase in muscle regeneration in mdx mice (treated at 1 and 2 months of age) with AAV-IKKadn (29.8 and 20.4%) or AAV-IKKb-dn (29.5 and 20.2%) when compared with controls treated with PBS (30.8 and 19.5%), AAV-IKKa-wt (29.0 and 18.7%) and AAV-IKKb-wt (27.3 and 22.5%). The absence of an effect on regeneration in mdx mice treated at a young age was surprising because of previous studies showing that three times weekly treatment with a peptide inhibitor of IKK, resulted in a significant enhancement of muscle regeneration. 22 One possible explanation for the differing results may lie in the difference between a peptide-based therapeutic that would be expected to act immediately and an AAV vector-based therapeutic that requires time, up to 2 weeks, for transgene expression.
In contrast to the results in young mdx mice, we observed improved skeletal muscle regeneration in mdx mice treated at 11 months of age. As described in Table 2 , there were significant increases in muscle regeneration in mdx mice (treated at 11 months of age) with AAVIKKa-dn (4.3%) or AAV-IKKb-dn (9.9%) when compared with controls treated with PBS (1.4%), AAV-IKKa-wt (0.9%) and AAV-IKKb-wt (0.8%). This result suggests that inhibition of pathological activation of NF-kB is effective at a time when the regenerative capacity of dystrophic muscle is significantly reduced. This result is of potential significant importance for its ultimate utility in the clinical treatment of dystrophic muscle as the dystrophic process in human DMD muscle is already well advanced even early in life.
The ability of dominant-negative IKKa and IKKb to reduce necrosis in old mdx muscle was also examined. Reduced levels of necrosis were observed in older mdx mice treated with AAV-IKKa-dn (15.4%) and AAV-IKKb-dn (15.1%) compared with age-matched control groups treated with PBS (34.0%), AAV-IKKa-wt (35.6%) and AAV-IKKb-wt (34.9%).
By using the ubiquitous CMV promoter for expression of the therapeutic constructs, the potential for transduction and expression in inflammatory cells, which originate from hematopoietic stem cells, recruited to dystrophic muscle tissue was preserved. As the inhibition of NF-kB activity could benefit dystrophic muscle through effects on inflammatory cells as well as muscle fibers, the observed therapeutic effects may reflect a combination of both mechanisms.
Although IKKb participates the 'classical' activation of NF-kB, IKKa is a component of 'alternative' activation of NF-kB. 34 Interestingly, our results suggest that targeting IKKa also inhibits the level of nuclear NF-kB in dystrophic muscle and enhances muscle regeneration. This result is in contrast to a previous study, 35 showing that transfection of the IKKa-dn plasmid into the C2C12 cell line had no significant effect on pro-inflammatory gene expression following LPS stimulation of myotubes. However, our results demonstrate that following AAVmediated gene transfer to muscle in vivo, IKKa-dn is as effective in improving pathology as IKKb-dn.
In summary, AAV-mediated gene transfer of dominant-negative IKK, either IKKb or IKKa, to block pathological NF-kB signaling is a promising strategy for the treatment of DMD. The current studies suggest effectiveness as an independent therapeutic, especially when the dystrophic process is more advanced. Furthermore, combination therapy for DMD with mini-dystrophin gene transfer or stem cell transplantation and inhibition of NF-kB activation may be synergistic and will be explored in future studies.
Materials and methods
Construction of IKKs and rAAV vector production
The pEF6B plasmids containing cDNAs of dominantnegative IKKa (IKKa-dn), wild-type IKKa (IKKa-wt), dominant-negative IKKb (IKKb-dn) and wild-type IKKb (IKKb-wt) served as templates for PCR to obtain different gene cloning sequences. The cDNA encoding for IKKa-dn had mutations at positions 130 (A-G) and 131 (A-C), which resulted in a point mutation (K4A) compared with IKKa-wt (GenBank, NM_001278.3), another cDNA encoding for IKKb-dn had a point mutations at positions 529-531 (A-G, G-A and T-A) and 541-542 (T-G and C-A), resulting in the changes of amino acids at both positions (S4E) compared with IKKb-wt (GenBank, NM_001556.1). The N-terminal primers used for amplification of IKKa-(dn and wt) and IKKb-(dn and wt) were 5 0 -ggccaccATG GAGCGGCCCCCGGGGC and 5 0 -ggccaccatgagctggt caccttccc, respectively; which include a kozak box (GCCACC) immediately in 5 0 terminus of the start codon to increase the level of transcription at the N-terminus. The C-terminal primers for IKKa and IKKb were 5 0 -gctca TCATTCTGTTAACCAACTCCAATC and 5 0 -gctcaTCATG AGGCCTGCTCCAGGC, respectively; both include a stop codon. The purified PCR products were electrophoresed as 2.2 kb bands, purified and treated with PNK enzyme (New England Biolabs, Beverly, MA, USA) to add a phosphate to the N-terminus. The fragments were inserted separately into the XhoI site of the single-stranded AAV vectors shuttle plasmids under the control of the CMV promoter. 23 The resulting clones were sequenced and purified twice by CsCl gradient to generate the serotype 2 of rAAV vector using a previously published protocol. 36 The vector titers were B3-5 Â 10 13 viral genome particles per ml as determined by dot blot assay.
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In vitro effects of IKKb-dn on mouse macrophages
To investigate the effect of IKKb-dn on cultured nonmuscle cells, mouse macrophage RAW cells from American Type Culture Collection (ATCC, Manassas, VA, USA) were seeded into six-well plates and cultured to 80% confluence. Transfections with rAAV plasmid DNAs were performed with a lipofectamine kit (Invitrogen, Carlsbad, CA, USA) according to a standard protocol. The medium was changed twice with Dulbecco's Modified Eagle Medium (DMEM) containing 10% fetal bovine serum and 1% penicillin/streptomycin (1% P/S v/v) at 6 and 24 h after transfection. Stimulation with LPS (Sigma, St Louis, MO, USA) was achieved by adding 100 ng ml À1 LPS to the medium for 24 h. An aliquot of 200 ml of culture medium was removed, and the levels of TNFa and IL-10 were determined using an enzyme-linked immunosorbent assay kit (R&D system, Minneapolis, MN, USA) according to the standard protocol provided by the manufacturer.
Mdx mice and rAAV vector administration
Mdx (C57BL/10ScSn-mdx/J) mice were purchased from Jackson Laboratory (Bar Harbor, ME, USA). All animal studies were approved by the University of Pittsburgh Animal Care and Use Committee. Thirty male mdx mice were divided into 1, 2 and 11-month-old age groups (10 mice per age group). In each age group, 10 mice were further distributed into five groups to receive a single intramuscular injection of one of four different AAV2 vectors (AAV2-IKKa-dn, AAV2-IKKa-wt, AAV2-IKKb-dn and AAV2-IKKbwt) at 1-2 Â 10 11 viral genome particles of AAV and PBS, as a control, at the volume of 30-50 ml bilaterally in TA and GAS muscles. Therefore, the number of mouse muscles for each group was four. All mice were killed at 1 month posttreatment, and the muscles were collected for quantitative analysis of NF-kB and muscle histology.
Efficiency of the gene transfer in vitro and in vivo
Before the in vivo study, we tested the gene transfer efficiencies of AAV vectors in 293 cells. The four groups of cells were transduced with AAV2-IKKa-dn, AAV2-IKKa-wt, AAV2-IKKb-dn and AAV2-IKKb-wt at an m.o.i of 2.5 Â 10 4 in six-well plate, and then were harvested for western blot analysis 48 h post-transduction according to the previously published methods. 24, 37 Briefly, cells were lysed in 100 ml of radioimmunoprecipitation assay buffer, and 10 ml of samples was performed for western blot analysis using the standard protocol. 37 Western blot was also carried out to determine the gene transfer in vivo, 25-30 cryosections (10 mm) of GAS muscles treated at 2 months of age and TA muscles treated at 11 months of age were lysed in 20 ml of radioimmunoprecipitation assay buffer, and 15 ml of samples was performed for western blot analysis. The rabbit polyclonal antibody against C-terminus of IKKa and IKKb (Abcam, Inc., Cambridge, MA, USA) were used because of this antibodies correspond respectively to the highly conserved C-terminus regions of IKKa and IKKb, both dominant-negative and wild-type forms. All in vitro transfection experiments in 293 cells were performed in triplicates. b-Actin (43 kDa) and glyceraldehyde-3-phosphate dehydrogenase (37 kDa) were used as markers to evaluate the amount of protein in each group used for western blot in vivo and in vivo, respectively.
NF-kB electrophoretic mobility shift assay
For NF-kB electrophoretic mobility shift assays to determine the level of nuclear NF-kB, a double-stranded DNA probe containing the NF-kB-binding sequence was radiolabeled with 32 P as previously described. 38 Briefly, 45 mg of nuclear extract from the indicated hindlimb muscle was incubated in 5 Â gel shift assay buffer (Promega, Fitchburgh, WI, USA), followed by the addition of a 32 P-radiolabeled NF-kB DNA probe. Reaction samples were electrophoresed on a 6% nondenaturing gel at 30 mA, which were then dried and imaged with autoradiographic film.
Analysis of muscle histology
Immunohistochemical analysis for embryonic myosin heavy chain was used to evaluate myogenic regeneration. The M.O.M. immunodetection kit (Vector Laboratories, Burlingame, CA, USA) and a mouse monoclonal antibody against embryonic myosin heavy chain (F1.652 from the Department of Biological Sciences, University of Iowa, IA, USA) were used. Fluorescently labeled secondary antibody was Cy 3 conjugated AffiniPure rabbit anti-mouse IgG (1:500; West Grove, PA, USA). To determine muscle fiber necrosis, muscle sections were incubated with fluorescein isothiocyanate-conjugated horse anti-mouse IgG at 1:100 dilution (Vector Laboratories), according to a published protocol. 39 
Statistical analysis
The significance of differences between groups of experiments was evaluated by analysis of variance or a two-tailed Student's t-test where appropriate. All results were expressed as the mean ± s.e.m. A P-value o0.05 was considered significant.
